SANP Stock Overview
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Sanofi Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €90.87 |
| 52 Week High | €106.00 |
| 52 Week Low | €83.34 |
| Beta | 0.45 |
| 11 Month Change | -8.12% |
| 3 Month Change | -9.32% |
| 1 Year Change | 6.81% |
| 33 Year Change | 4.31% |
| 5 Year Change | 7.47% |
| Change since IPO | 56.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| SANP | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -0.8% | -2.3% | 0.8% |
| 1Y | 6.8% | -2.7% | 6.6% |
Return vs Industry: SANP exceeded the UK Pharmaceuticals industry which returned -2.8% over the past year.
Return vs Market: SANP matched the UK Market which returned 6.1% over the past year.
Price Volatility
| SANP volatility | |
|---|---|
| SANP Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SANP has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: SANP's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 86,088 | Paul Hudson | www.sanofi.com |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Sanofi Fundamentals Summary
| SANP fundamental statistics | |
|---|---|
| Market cap | €113.91b |
| Earnings (TTM) | €4.51b |
| Revenue (TTM) | €48.45b |
25.3x
P/E Ratio2.4x
P/S RatioIs SANP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANP income statement (TTM) | |
|---|---|
| Revenue | €48.45b |
| Cost of Revenue | €14.96b |
| Gross Profit | €33.48b |
| Other Expenses | €28.98b |
| Earnings | €4.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | 3.59 |
| Gross Margin | 69.12% |
| Net Profit Margin | 9.30% |
| Debt/Equity Ratio | 32.5% |
How did SANP perform over the long term?
See historical performance and comparison